Young people left in limbo, caught between a ban and the hope of evidence
In the long and unresolved debate over how medicine should respond to gender-questioning youth, the United Kingdom has taken a careful step forward: regulators have set minimum age thresholds for children to enter a clinical trial of puberty-blocking drugs, a study designed to generate the very evidence that has been missing from this field. The Pathways Trial, paused earlier this year over safety concerns, will now proceed with strengthened protections — parental consent, clearer stopping criteria, and more detailed conversations about fertility — as researchers at King's College London prepare to begin recruitment in August 2026. The decision arrives two years after a national ban left many young people without access to a treatment they had been receiving, and it unfolds against a backdrop of legal challenges that may yet delay or derail the trial. At its heart, this is a story about what societies owe children when the science is uncertain and the suffering is real.
- Gender-questioning children have been living in a painful gap since 2024, when the UK banned puberty blockers for under-18s and left many without a treatment they had come to rely on.
- The Pathways Trial was meant to fill that evidence void, but its own pause in February 2026 deepened the uncertainty, forcing regulators and researchers to renegotiate the terms under which it could safely proceed.
- New safeguards — minimum ages of 11 and 12, mandatory parental consent, clearer guidance on when to stop treatment, and expanded fertility discussions — represent a hard-won compromise between urgency and caution.
- Legal challenges from clinicians and campaigners who question the ethics of the trial and the capacity of children to give meaningful informed consent now threaten to delay recruitment past the August target.
- Dr. Hilary Cass, whose review prompted the original ban, has warned that blocking the trial will not protect children — it will push them toward unregulated online suppliers operating without oversight or evidence.
- The young people waiting on the outcome are caught between a ban that removed their options and a trial that may yet offer a path — their distress is the quiet centre of a very loud debate.
The Pathways Trial, a clinical study of puberty-blocking drugs in gender-questioning children, will move forward in the United Kingdom with a new minimum age requirement — 11 for those registered female at birth, 12 for those registered male — after months of regulatory scrutiny and a formal pause imposed in February 2026. The Medicines and Healthcare products Regulatory Agency had flagged safety concerns and proposed age thresholds where none had previously existed. Through negotiations with the research team at King's College London, a modified protocol has now been agreed upon.
The trial exists because of a gap. In 2024, following a major review by Dr. Hilary Cass examining the evidence base for gender medicine, the UK banned puberty blockers for anyone under 18 questioning their gender identity. That decision left many young people without access to a treatment they had been receiving, and advocates have described the intervening period as one of real emotional and physical distress. The Pathways Trial is designed to measure how these drugs affect the physical, social, and emotional wellbeing of children under 16 who are distressed about their gender and already engaged with gender services.
The new safeguards go beyond age limits. All participants must have parental consent and demonstrate a genuine understanding of the risks involved. Researchers have strengthened the information provided to families and introduced clearer criteria for stopping treatment — including concerns about bone density, brain function, or unexpected bleeding. Fertility preservation has become a more prominent part of the conversation with prospective participants.
The trial remains deeply contested. Clinicians and campaigners are pursuing legal action, arguing that children cannot meaningfully consent to a treatment that may affect their future ability to have biological children. They are challenging the MHRA, the government, and others involved. Professor Sir Jonathan Montgomery of UCL noted that legal proceedings will provide additional scrutiny — and that if something important has been overlooked, it is better to surface it now.
Dr. Cass herself has urged the trial to proceed, warning that without it, the vacuum will be filled by unregulated practitioners selling puberty blockers online, outside any framework of evidence or oversight. The LGBTQ+ charity Stonewall has expressed support for the modified protocol, noting that young people have been waiting in limbo since the ban.
Recruitment is expected to begin in August 2026, though researchers have agreed not to enroll participants until legal proceedings have had time to continue. For the children caught between a ban and a trial, between distress and the hope of evidence, what happens next carries enormous weight.
The Pathways Trial, a clinical study examining puberty-blocking drugs in gender-questioning children, will now require participants to be at least 11 years old—a threshold set by UK regulators after months of scrutiny and safety concerns. The trial had been paused in February 2026 when the Medicines and Healthcare products Regulatory Agency flagged worries about the research and proposed a minimum age requirement where none had previously existed. Through discussions with the research team at King's College London, regulators have now agreed to move forward with strengthened protections, though the path to recruitment remains uncertain.
The stakes of this decision run deep. In 2024, the UK banned puberty blockers for anyone under 18 questioning their gender identity, a move that followed a major review by Dr. Hilary Cass examining the evidence base for gender medicine. That ban left many young people without access to a treatment they had been receiving, creating what advocates describe as a period of emotional and physical distress. The Pathways Trial is designed to fill that evidence gap—to measure how these drugs affect the physical, social, and emotional wellbeing of children under 16 who are distressed about their gender and already engaged with gender services. The trial was initially approved by UK regulators and ethics experts in November 2025, but the MHRA's February pause forced a reckoning about how to proceed safely.
The new safeguards reflect that tension. Children will need to be at least 11 if registered female at birth, or 12 if registered male at birth. All participants will require parental consent and must demonstrate a solid understanding of what the intervention involves and what risks it carries. The researchers have also strengthened the information provided to young people and their families, and introduced clearer guidance about when the drugs should be stopped—if bone density becomes a concern, if there are questions about brain function, or if unexpected bleeding occurs. Fertility preservation is now a more detailed part of the conversation.
Yet the trial remains contested. Some doctors have questioned whether it is necessary at all. Campaigners and clinicians are pursuing legal action, arguing that the research is unethical and that children cannot truly give informed consent to a treatment that might affect their ability to have biological children in the future. They are challenging the MHRA, the government, and others involved in the trial. Professor Sir Jonathan Montgomery, a health care law expert at UCL, noted that legal proceedings will provide additional scrutiny, and that if regulators have missed something important, it is better to clarify it now than later.
Dr. Cass, whose 2024 review prompted the ban, has since told the BBC that the trial must go ahead. Without it, she warned, the vacuum will be filled by unregulated practitioners selling puberty blockers online and through private channels—drugs handed out without proper oversight or evidence. The trial, in her view, is the responsible path forward. The LGBTQ+ charity Stonewall has expressed support for the modified protocol, emphasizing that young people have been waiting in limbo since the ban, caught between a treatment they cannot access and a condition that causes them real distress.
Recruitment is expected to begin in August 2026, though the researchers have agreed not to enroll participants until after that date to allow legal proceedings to continue. The King's College team has said they welcome scrutiny of research involving children and young people, and that while they have strengthened safeguards and information materials, there are no major changes to the trial's core design or conduct. What happens next depends partly on the courts, partly on whether the legal challenges succeed in blocking the trial, and partly on whether the modifications prove sufficient to address the concerns that have been raised. For the young people waiting—caught between a ban and a trial, between distress and the hope of evidence—the outcome matters enormously.
Citações Notáveis
We're going to have ongoing charlatans just handing out inappropriate drugs if the trial doesn't go ahead, particularly through online sales— Dr. Hilary Cass, author of 2024 gender medicine review
Many young people have been left in limbo since the ban, in emotional and physical distress— Stonewall spokesperson
A Conversa do Hearth Outra perspectiva sobre a história
Why did regulators pause this trial in the first place? What specifically worried them?
The MHRA raised safety concerns about how the trial was structured and who could participate. They suggested a minimum age of 14 when the original protocol had no age floor at all. That's a significant gap—they wanted to know the trial was protecting younger children adequately.
And the researchers agreed to age 11 instead of 14. That's still quite young. Why not go with what the regulator suggested?
The researchers negotiated. They argued that 11 and 12 were appropriate thresholds given the population they're studying—children already in gender services, already distressed, already engaged with the healthcare system. It's a compromise, not a capitulation.
What about the legal challenges? Are those likely to succeed?
That's genuinely uncertain. The campaigners are arguing informed consent is impossible for children, especially around fertility. A law professor I read said the legal process itself might clarify things the regulators missed. But no one knows how courts will rule.
If the trial doesn't happen, what's the alternative?
That's the hard part. Dr. Cass warned that without a legitimate trial, young people will turn to unregulated sources—online pharmacies, private clinics operating without oversight. The ban created a vacuum, and nature abhors a vacuum.
So some young people are suffering now because of the ban?
Yes. Stonewall said many are in emotional and physical distress, waiting in limbo. They had access to blockers, then suddenly didn't. The trial is meant to be a way out of that, but only if it actually happens.
When will we know if it's moving forward?
August is when recruitment was supposed to start, but the legal cases might delay that. The courts will have their say first. It's a waiting game for everyone involved.